Free Trial

CRISPR Therapeutics (CRSP) Competitors

CRISPR Therapeutics logo
$41.36 +0.08 (+0.19%)
Closing price 04:00 PM Eastern
Extended Trading
$41.32 -0.03 (-0.08%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CRSP vs. NBIX, EXEL, MRNA, QGEN, TECH, RVMD, RGEN, HALO, ADMA, and PCVX

Should you be buying CRISPR Therapeutics stock or one of its competitors? The main competitors of CRISPR Therapeutics include Neurocrine Biosciences (NBIX), Exelixis (EXEL), Moderna (MRNA), Qiagen (QGEN), Bio-Techne (TECH), Revolution Medicines (RVMD), Repligen (RGEN), Halozyme Therapeutics (HALO), ADMA Biologics (ADMA), and Vaxcyte (PCVX). These companies are all part of the "biological products, except diagnostic" industry.

CRISPR Therapeutics vs. Its Competitors

CRISPR Therapeutics (NASDAQ:CRSP) and Neurocrine Biosciences (NASDAQ:NBIX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, community ranking, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

CRISPR Therapeutics presently has a consensus price target of $71.75, indicating a potential upside of 73.48%. Neurocrine Biosciences has a consensus price target of $162.00, indicating a potential upside of 30.24%. Given CRISPR Therapeutics' higher probable upside, equities research analysts clearly believe CRISPR Therapeutics is more favorable than Neurocrine Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CRISPR Therapeutics
1 Sell rating(s)
7 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.50
Neurocrine Biosciences
0 Sell rating(s)
3 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.86

Neurocrine Biosciences received 559 more outperform votes than CRISPR Therapeutics when rated by MarketBeat users. Likewise, 77.70% of users gave Neurocrine Biosciences an outperform vote while only 64.37% of users gave CRISPR Therapeutics an outperform vote.

CompanyUnderperformOutperform
CRISPR TherapeuticsOutperform Votes
486
64.37%
Underperform Votes
269
35.63%
Neurocrine BiosciencesOutperform Votes
1045
77.70%
Underperform Votes
300
22.30%

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are held by institutional investors. 4.3% of CRISPR Therapeutics shares are held by company insiders. Comparatively, 4.8% of Neurocrine Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

CRISPR Therapeutics has a beta of 1.75, indicating that its stock price is 75% more volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500.

In the previous week, Neurocrine Biosciences had 6 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 19 mentions for Neurocrine Biosciences and 13 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.79 beat Neurocrine Biosciences' score of 0.76 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CRISPR Therapeutics
5 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Neurocrine Biosciences
8 Very Positive mention(s)
0 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Neurocrine Biosciences has a net margin of 14.49% compared to CRISPR Therapeutics' net margin of -981.54%. Neurocrine Biosciences' return on equity of 13.38% beat CRISPR Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CRISPR Therapeutics-981.54% -18.46% -15.79%
Neurocrine Biosciences 14.49%13.38%9.73%

Neurocrine Biosciences has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISPR Therapeutics$35M102.06-$366.25M-$4.52-9.15
Neurocrine Biosciences$2.41B5.10$341.30M$2.9542.17

Summary

Neurocrine Biosciences beats CRISPR Therapeutics on 14 of the 18 factors compared between the two stocks.

Get CRISPR Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRSP vs. The Competition

MetricCRISPR TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$3.57B$3.09B$5.56B$8.50B
Dividend YieldN/A1.56%5.28%4.16%
P/E Ratio-9.4632.6326.6419.64
Price / Sales102.06455.18407.99152.17
Price / CashN/A168.6838.2534.64
Price / Book1.843.366.974.60
Net Income-$366.25M-$72.35M$3.23B$248.06M
7 Day Performance-1.19%0.31%-0.98%-1.03%
1 Month Performance11.12%17.20%7.70%3.50%
1 Year Performance-36.62%-17.84%31.32%12.68%

CRISPR Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRSP
CRISPR Therapeutics
3.4203 of 5 stars
$41.36
+0.2%
$71.75
+73.5%
-36.3%$3.57B$35M-9.46473Analyst Revision
Gap Down
NBIX
Neurocrine Biosciences
4.8811 of 5 stars
$126.00
+0.5%
$162.00
+28.6%
-7.1%$12.47B$2.41B38.291,200Analyst Revision
EXEL
Exelixis
4.5124 of 5 stars
$42.96
-0.2%
$39.35
-8.4%
+89.4%$11.71B$2.30B24.261,220Positive News
Analyst Forecast
MRNA
Moderna
4.4446 of 5 stars
$28.30
+3.1%
$53.58
+89.3%
-81.5%$10.93B$3.14B-3.053,900Trending News
Gap Down
QGEN
Qiagen
3.336 of 5 stars
$46.30
+1.8%
$48.42
+4.6%
+10.2%$10.29B$2.00B128.946,030
TECH
Bio-Techne
4.8474 of 5 stars
$50.10
+2.9%
$72.00
+43.7%
-33.5%$7.86B$1.21B50.643,000
RVMD
Revolution Medicines
4.4239 of 5 stars
$40.99
-0.2%
$67.08
+63.7%
+2.8%$7.63B$742K-11.41250Positive News
RGEN
Repligen
4.7868 of 5 stars
$132.29
+3.1%
$173.25
+31.0%
-8.1%$7.47B$650.43M-260.802,020
HALO
Halozyme Therapeutics
4.9071 of 5 stars
$54.63
+0.7%
$61.90
+13.3%
+9.8%$6.73B$1.08B15.92390Positive News
ADMA
ADMA Biologics
2.1719 of 5 stars
$21.06
+2.2%
$24.25
+15.1%
+100.4%$5.05B$459.38M75.50530Positive News
Insider Trade
Analyst Revision
PCVX
Vaxcyte
3.1458 of 5 stars
$37.30
+0.8%
$136.50
+266.0%
-53.4%$4.80BN/A-8.09160Positive News
Analyst Revision
Gap Down

Related Companies and Tools


This page (NASDAQ:CRSP) was last updated on 6/13/2025 by MarketBeat.com Staff
From Our Partners